Context Therapeutics Announces Chief Medical Officer Transition

Company Announcement - Context Therapeutics Inc. has appointed Dr. Karen Smith as interim Chief Medical Officer, replacing Dr. Claudio Dansky Ullmann, who will leave the company on May 10, 2025 [1] - Dr. Smith will maintain her role on the Board of Directors while serving as interim CMO, ensuring continuity in the company's clinical development programs [1][3] Leadership Experience - Dr. Smith has over 20 years of experience in the biopharmaceutical industry, previously serving as Global Head of Research & Development and CMO at Jazz Pharmaceuticals [2] - She has held senior leadership positions at Allergan, AstraZeneca, and Bristol Myers Squibb, contributing to her expertise in drug development [2] Company Focus - Context Therapeutics is focused on advancing T cell engaging bispecific antibodies for solid tumors, with a portfolio that includes CTIM-76, CT-95, and CT-202 [3] - The company is headquartered in Philadelphia and aims to innovate in the field of T cell engaging therapeutics [3]